NORML
APRIL 8, 2020
The National Organization for the Reform of Marijuana Laws (NORML) has formally submitted comments to the US Federal Register opposing the Drug Enforcement Administration’s proposed rule changes governing the federal production and distribution of cannabis for clinical research purposes.
Americans for Safe Access
JUNE 2, 2020
On March 23, DEA published a proposed rulemaking —“Controls to Enhance the Cultivation of Marihuana for Research in the United States”—in the Federal Register (85 FR 16292), involving who can grow cannabis in bulk for research purposes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
JUNE 16, 2021
Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. . This relationship enables us to initiate our clinical research program and marks an important step for Wake in Canada.
NORML
JULY 26, 2019
Federal officials have approved plans for the University of Mississippi to grow 2,000 kilograms (4,409 pounds) of cannabis to provide to investigators for clinical trial research. Clinicians wishing to conduct FDA-approved clinical trials on cannabis have long complained that federally-provided samples are of inferior quality.
NORML
APRIL 15, 2019
Marijuana grown by the University of Mississippi for clinical research purposes is genetically divergent from strains of cannabis commercially available in retail markets, according to an analysis prepared by researchers at the University of Northern Colorado.
NORML
OCTOBER 21, 2019
A federal court on Friday denied a petition for a writ of mandamus that sought to order the US Drug Enforcement Administration to begin licensing private entities that wish to cultivate cannabis. The agency in 2016 first announced its intent to license private entities to grow cannabis for FDA-approved clinical trials.
NORML
MARCH 1, 2019
.” He later acknowledged that these restrictions have led many “companies [to] go overseas to conduct research with foreign-grown product that is more easily sourced for the purposes of clinical trials.” ” Although that ruling ordered DEA to lift the ban, the agency failed to do so.
Expert insights. Personalized for you.
341 
Let's personalize your content